查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1855972

2025年全球罕见血液疾病市场报告

Rare Hematology Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，罕见血液疾病市场规模呈现强劲成长，预计从2024年的144.6亿美元成长到2025年的154.7亿美元，复合年增长率达7.0%。这一增长主要受以下因素驱动：专科治疗中心数量增加、血液病学学术研究经费增长、医生对罕见血液病的认识提高、生物样本库和登记库的使用日益增多，以及由于监测系统加强而导致的病例报告改进。

预计未来几年，罕见血液疾病市场将保持强劲成长，到2029年市场规模将达到199.8亿美元，复合年增长率（CAGR）为6.6%。预测期内的成长将主要得益于靶向生技药品研发管线的不断拓展、精准诊断技术的日益普及、罕见病研究领域跨境合作的不断深化、患者支持数位平台的研发以及对预防性遗传咨询的日益重视。预测期内的关键趋势包括免疫疗法的进步、干细胞移植技术的改进、数位健康平台在血液疾病领域的应用、技术主导的药物研发模式以及基于生物标记的诊断方法的开发。

预计未来几年，罕见血液疾病盛行率的不断上升将推动罕见血液疾病市场的成长。罕见血液疾病是指影响血球和凝血因子生成、功能和寿命的罕见疾病，会导致贫血、出血和溶血。这些疾病的盛行率上升主要是由于基因突变和遗传性疾病，即异常基因从父母遗传给子女。罕见血液疾病市场在应对这些疾病方面发挥关键作用，提供专业的诊断和标靶治疗，以有效管理复杂罕见的血液疾病。这些服务能够实现标靶治疗和持续的患者照护，减少併发症，最终改善患者的健康状况和生活品质。例如，总部位于澳洲的非营利组织珀斯血液研究所于2024年4月报告称，被诊断患有血友病（一种影响血液凝固的遗传性血液疾病）的人数从2021年的233,577人增加到2022年的257,146人。因此，罕见血液疾病盛行率的上升正在推动罕见血液疾病市场的扩张。

罕见血液疾病领域的公司正日益专注于开发创新治疗方法，并建立策略性倡议，例如成立多方相关利益者倡导委员会，以满足未被满足的医疗需求、加强患者支持并推进各种疾病的解决方案。多方利害关係人倡导委员会汇集患者、看护者和专家，共同合作，改善特定疾病的照护、提高公众意识并寻求解决方案。例如，2023年2月，美国生物製药公司Agios 相关利益者推出了「红血球革命倡议咨询委员会」。该委员会专注于罕见溶血性贫血，包括丙酮酸激酶缺乏症、地中海贫血和镰状细胞贫血。委员会旨在加强社区联繫、发表研究证据、提出切实可行的解决方案，并提高公众对通用挑战的认识。这包括赞助播客、製作影片内容，以及与美国国家罕见疾病组织等机构伙伴关係，以促进健康公平和教育。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税，以及新冠疫情及其復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球罕见血液疾病：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 终端用户产业分析
  • 全球罕见血液疾病市场：成长率分析
  • 全球罕见血液疾病市场表现：规模与成长，2019-2024年
  • 全球罕见血液疾病市场预测：规模与成长，2024-2029年，2034年
  • 全球罕见血液疾病：潜在市场规模 (TAM)

第六章 市场细分

  • 全球罕见血液疾病市场依疾病类型、表现及预测划分，2019-2024年、2024-2029年、2034年
  • 血友病
  • 镰状细胞性贫血症
  • 地中海型贫血
  • 骨髓发育不良症候群
  • 其他疾病类型
  • 全球罕见血液疾病市场依治疗类型划分：绩效及预测，2019-2024年、2024-2029年、2034年
  • 基因治疗
  • 干细胞移植
  • 输血
  • 药物治疗
  • 全球罕见血液疾病市场（依诊断技术划分）：绩效及预测，2019-2024年、2024-2029年、2034年
  • 实验室测试
  • 血液检查
  • 骨髓切片检查
  • 成像技术
  • 磁振造影（MRI）扫描
  • 超音波
  • 基因检测
  • 携带者筛检
  • 全基因组定序
  • 全球罕见血液疾病市场按应用、效能和预测划分，2019-2024年、2024-2029年、2034年
  • 儿童
  • 成人
  • 全球罕见血液疾病市场依最终用户、绩效及预测划分，2019-2024年、2024-2029年、2034年
  • 医院
  • 专科诊所
  • 研究所
  • 全球罕见血液疾病市场：依血友病类型细分、绩效及预测（2019-2024年、2024-2029年、2034年）
  • A型血友病A
  • B型血友病
  • 血友病C
  • 后天性血友病
  • 全球罕见血液疾病市场：镰状细胞疾病、类型、表现和预测进行细分，2019-2024年、2024-2029年、2034年
  • 镰状细胞贫血症
  • 镰状血红素C疾病
  • 镰状细胞β-地中海贫血
  • 全球罕见血液疾病市场：依地中海型贫血类型细分、绩效及预测（2019-2024年、2024-2029年、2034年）
  • α-地中海贫血
  • β-地中海型贫血
  • 全球罕见血液疾病市场：细分市场（骨髓发育不良症候群症候群），依类型、疗效及预测（2019-2024年、2024-2029年、2034年）
  • 难治性贫血（RA）
  • 伴随环状铁粒幼细胞的难治性贫血（RARS）
  • 难治性多系发育不良性血球减少症（RCMD）
  • 难治性贫血伴随原细胞增多（RAEB）
  • 伴随孤立性 Del(5Q) 的骨髓发育不良症候群
  • 未分类骨髓发育不良症候群
  • 全球罕见血液疾病市场：依其他疾病类型细分，实际数据与预测，2019-2024年、2024-2029年、2034年
  • 再生障碍性贫血
  • 阵发性夜间血尿症
  • 罕见凝血障碍

第七章 区域和国家分析

  • 全球罕见血液疾病市场：依地区、绩效及预测划分，2019-2024年、2024-2029年、2034年
  • 全球罕见血液疾病市场：国家、表现及预测，2019-2024年、2024-2029年、2034年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第十八章：法国市场

第十九章：义大利市场

第二十章：西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第三十章：竞争格局与公司概况

  • 罕见血液疾病市场：竞争格局
  • 罕见血液疾病市场：公司简介
    • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Novartis AG
  • Astrazeneca Plc
  • Bristol-Myers Squibb Company
  • Takeda Pharmaceutical Company Limited
  • Amgen Inc.
  • CSL Behring LLC
  • Biogen Inc.
  • Jazz Pharmaceuticals Plc
  • Octapharma AG
  • PharmaEssentia Corporation
  • Disc Medicine Inc.
  • BioInvent International AB
  • Mustang Bio Inc.
  • BlueSphere Bio Inc.
  • Rallybio LLC

第32章 全球市场竞争基准化分析与仪錶板

第33章 重大併购

第34章 近期市场趋势

第35章：高潜力市场国家、细分市场与策略

  • 2029年罕见血液疾病市场：蕴藏新机会的国家
  • 2029年罕见血液疾病市场：新兴细分市场机会
  • 2029年罕见血液疾病市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章附录

简介目录
Product Code: r38624

Rare hematology refers to the study, diagnosis, and treatment of uncommon blood disorders, including rare anemias, clotting disorders, bone marrow failure syndromes, and rare blood cancers. These conditions often affect small patient populations and have limited treatment options. Rare hematology advances understanding, improves diagnosis, and supports the development of targeted therapies to enhance patient outcomes and quality of life.

The primary disease types in rare hematology include hemophilia, sickle cell disease, thalassemia, myelodysplastic syndromes, and others. Hemophilia is a genetic bleeding disorder characterized by insufficient clotting factors, leading to excessive bleeding and difficulty controlling hemorrhages. Treatments include gene therapy, stem cell transplantation, blood transfusion, and pharmacotherapy, supported by diagnostic techniques such as laboratory tests, blood tests, bone marrow biopsies, imaging methods, MRI scans, ultrasounds, genetic testing, carrier screening, and whole genome sequencing. Applications span both pediatric and adult populations, serving end users including hospitals, specialty clinics, and research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The rare hematology market research report is one of a series of new reports from The Business Research Company that provides rare hematology market statistics, including rare hematology industry global market size, regional shares, competitors with a rare hematology market share, detailed rare hematology market segments, market trends and opportunities, and any further data you may need to thrive in the rare hematology industry. This rare hematology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The rare hematology market size has grown strongly in recent years. It will grow from $14.46 billion in 2024 to $15.47 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period was driven by increasing availability of specialized treatment centers, rising academic research funding in hematology, growing physician awareness of rare blood conditions, expanding use of biobanking and registries, and improved incidence reporting through enhanced surveillance systems.

The rare hematology market size is expected to see strong growth in the next few years. It will grow to $19.98 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth during the forecast period is fueled by a growing pipeline of targeted biologics, rising adoption of precision diagnostics, expanding cross-border collaborations for rare disease research, development of digital platforms for patient support, and increasing emphasis on preventive genetic counseling. The primary trends in the forecast period include advancements in immunotherapy approaches, improvements in stem cell transplantation methods, integration of digital health platforms in hematology, technology-driven drug discovery models, and developments in biomarker-based diagnostics.

The increasing prevalence of rare blood disorders is expected to drive the growth of the rare hematology market in the coming years. Rare blood disorders are uncommon conditions that affect the production, function, or lifespan of blood cells or clotting factors, leading to anemia, bleeding, or hemolysis. The rising prevalence of these disorders is primarily due to genetic mutations and inherited conditions, where abnormal genes are passed down from parents to children. The rare hematology market plays a crucial role in addressing these conditions by providing specialized diagnostics and targeted therapies, ideal for managing complex and uncommon blood disorders. These services reduce complications by enabling precise treatment and continuous patient care, ultimately improving health outcomes and quality of life. For example, in April 2024, the Perth Blood Institute, an Australia-based nonprofit, reported that the number of people diagnosed with hemophilia, a genetic blood disorder that impairs blood clotting, increased to 257,146 in 2022 from 233,577 in 2021. As a result, the growing prevalence of rare blood disorders is fueling the expansion of the rare hematology market.

Companies in the rare hematology market are increasingly focusing on developing innovative therapies and establishing strategic initiatives, such as multi-stakeholder advocacy councils, to address unmet medical needs, enhance patient support, and drive solutions across various conditions. Multi-stakeholder advocacy councils bring together patients, caregivers, and experts to collaborate on improving care, awareness, and solutions for specific health conditions. For instance, in February 2023, Agios Pharmaceuticals Inc., a US-based biopharmaceutical company, launched the Red Cell Revolution advocacy advisory council. This initiative focuses on rare hemolytic anemias, including pyruvate kinase deficiency, thalassemia, and sickle cell disease. The council aims to strengthen community connections, generate published evidence, create practical solutions, and raise awareness of common challenges. It includes initiatives such as sponsored podcasts, video content, and partnerships with organizations such as the National Organization for Rare Disorders to promote health equity and education.

In October 2022, Pfizer Inc., a US-based biopharmaceutical company, acquired Global Blood Therapeutics Inc. for an undisclosed amount. This acquisition allows Pfizer to expand its rare hematology portfolio, particularly in sickle cell disease, enhancing its pipeline of therapies for underserved patient populations. Global Blood Therapeutics Inc. is a US-based biopharmaceutical company focused on developing therapies for rare blood disorders, especially sickle cell disease.

Major players in the rare hematology market are F. Hoffmann-La Roche Ltd, Pfizer Inc., Abbvie Inc., Bayer AG, Sanofi S.A., Novartis AG, Astrazeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Behring LLC, Biogen Inc., Jazz Pharmaceuticals Plc, Octapharma AG, PharmaEssentia Corporation, Disc Medicine Inc., BioInvent International AB, Mustang Bio Inc., BlueSphere Bio Inc., and Rallybio LLC.

North America was the largest region in the rare hematology market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in rare hematology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rare hematology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rare hematology market includes revenues earned by entities through genetic testing, disease monitoring, blood transfusion support, patient care management, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rare Hematology Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rare hematology market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rare hematology ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The rare hematology market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Disease Type: Hemophilia; Sickle Cell Disease; Thalassemia; Myelodysplastic Syndromes; Other Disease Types
  • 2) By Treatment Type: Gene Therapy; Stem Cell Transplantation; Blood Transfusion; Pharmacotherapy
  • 3) By Diagnostic Technique: Laboratory Tests; Blood Tests; Bone Marrow Biopsies; Imaging Techniques; Magnetic Resonance Imaging (MRI) Scans; Ultrasounds; Genetic Testing; Carrier Screening; Whole Genome Sequencing
  • 4) By Application: Pediatric; Adult
  • 5) By End-User: Hospitals; Specialty Clinics; Research Institutes
  • Subsegments:
  • 1) By Hemophilia: Hemophilia A; Hemophilia B; Hemophilia C; Acquired Hemophilia
  • 2) By Sickle Cell Disease: Sickle Cell Anemia; Sickle Hemoglobin C Disease; Sickle Beta Thalassemia
  • 3) By Thalassemia: Alpha Thalassemia; Beta Thalassemia
  • 4) By Myelodysplastic Syndromes: Refractory Anemia (RA); Refractory Anemia With Ring Sideroblasts (RARS); Refractory Cytopenia With Multilineage Dysplasia (RCMD); Refractory Anemia With Excess Blasts (RAEB); Myelodysplastic Syndrome With Isolated Del(5Q); Unclassified Myelodysplastic Syndromes
  • 5) By Other Disease Types: Aplastic Anemia; Paroxysmal Nocturnal Hemoglobinuria; Rare Coagulation Disorders
  • Companies Mentioned: F. Hoffmann-La Roche Ltd; Pfizer Inc.; Abbvie Inc.; Bayer AG; Sanofi S.A.; Novartis AG; Astrazeneca Plc; Bristol-Myers Squibb Company; Takeda Pharmaceutical Company Limited; Amgen Inc.; CSL Behring LLC; Biogen Inc.; Jazz Pharmaceuticals Plc; Octapharma AG; PharmaEssentia Corporation; Disc Medicine Inc.; BioInvent International AB; Mustang Bio Inc.; BlueSphere Bio Inc.; Rallybio LLC
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Rare Hematology Market Characteristics

3. Rare Hematology Market Trends And Strategies

4. Rare Hematology Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Rare Hematology Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Rare Hematology PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Rare Hematology Market Growth Rate Analysis
  • 5.4. Global Rare Hematology Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Rare Hematology Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Rare Hematology Total Addressable Market (TAM)

6. Rare Hematology Market Segmentation

  • 6.1. Global Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hemophilia
  • Sickle Cell Disease
  • Thalassemia
  • Myelodysplastic Syndromes
  • Other Disease Types
  • 6.2. Global Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gene Therapy
  • Stem Cell Transplantation
  • Blood Transfusion
  • Pharmacotherapy
  • 6.3. Global Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Laboratory Tests
  • Blood Tests
  • Bone Marrow Biopsies
  • Imaging Techniques
  • Magnetic Resonance Imaging (MRI) Scans
  • Ultrasounds
  • Genetic Testing
  • Carrier Screening
  • Whole Genome Sequencing
  • 6.4. Global Rare Hematology Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pediatric
  • Adult
  • 6.5. Global Rare Hematology Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Research Institutes
  • 6.6. Global Rare Hematology Market, Sub-Segmentation Of Hemophilia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Acquired Hemophilia
  • 6.7. Global Rare Hematology Market, Sub-Segmentation Of Sickle Cell Disease, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Sickle Cell Anemia
  • Sickle Hemoglobin C Disease
  • Sickle Beta Thalassemia
  • 6.8. Global Rare Hematology Market, Sub-Segmentation Of Thalassemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Alpha Thalassemia
  • Beta Thalassemia
  • 6.9. Global Rare Hematology Market, Sub-Segmentation Of Myelodysplastic Syndromes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Refractory Anemia (RA)
  • Refractory Anemia With Ring Sideroblasts (RARS)
  • Refractory Cytopenia With Multilineage Dysplasia (RCMD)
  • Refractory Anemia With Excess Blasts (RAEB)
  • Myelodysplastic Syndrome With Isolated Del(5Q)
  • Unclassified Myelodysplastic Syndromes
  • 6.10. Global Rare Hematology Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Aplastic Anemia
  • Paroxysmal Nocturnal Hemoglobinuria
  • Rare Coagulation Disorders

7. Rare Hematology Market Regional And Country Analysis

  • 7.1. Global Rare Hematology Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Rare Hematology Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rare Hematology Market

  • 8.1. Asia-Pacific Rare Hematology Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rare Hematology Market

  • 9.1. China Rare Hematology Market Overview
  • 9.2. China Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rare Hematology Market

  • 10.1. India Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rare Hematology Market

  • 11.1. Japan Rare Hematology Market Overview
  • 11.2. Japan Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rare Hematology Market

  • 12.1. Australia Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rare Hematology Market

  • 13.1. Indonesia Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rare Hematology Market

  • 14.1. South Korea Rare Hematology Market Overview
  • 14.2. South Korea Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rare Hematology Market

  • 15.1. Western Europe Rare Hematology Market Overview
  • 15.2. Western Europe Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rare Hematology Market

  • 16.1. UK Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rare Hematology Market

  • 17.1. Germany Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rare Hematology Market

  • 18.1. France Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rare Hematology Market

  • 19.1. Italy Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rare Hematology Market

  • 20.1. Spain Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rare Hematology Market

  • 21.1. Eastern Europe Rare Hematology Market Overview
  • 21.2. Eastern Europe Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rare Hematology Market

  • 22.1. Russia Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rare Hematology Market

  • 23.1. North America Rare Hematology Market Overview
  • 23.2. North America Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rare Hematology Market

  • 24.1. USA Rare Hematology Market Overview
  • 24.2. USA Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rare Hematology Market

  • 25.1. Canada Rare Hematology Market Overview
  • 25.2. Canada Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rare Hematology Market

  • 26.1. South America Rare Hematology Market Overview
  • 26.2. South America Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rare Hematology Market

  • 27.1. Brazil Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rare Hematology Market

  • 28.1. Middle East Rare Hematology Market Overview
  • 28.2. Middle East Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rare Hematology Market

  • 29.1. Africa Rare Hematology Market Overview
  • 29.2. Africa Rare Hematology Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Rare Hematology Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Rare Hematology Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rare Hematology Market Competitive Landscape And Company Profiles

  • 30.1. Rare Hematology Market Competitive Landscape
  • 30.2. Rare Hematology Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Abbvie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. Rare Hematology Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Astrazeneca Plc
  • 31.3. Bristol-Myers Squibb Company
  • 31.4. Takeda Pharmaceutical Company Limited
  • 31.5. Amgen Inc.
  • 31.6. CSL Behring LLC
  • 31.7. Biogen Inc.
  • 31.8. Jazz Pharmaceuticals Plc
  • 31.9. Octapharma AG
  • 31.10. PharmaEssentia Corporation
  • 31.11. Disc Medicine Inc.
  • 31.12. BioInvent International AB
  • 31.13. Mustang Bio Inc.
  • 31.14. BlueSphere Bio Inc.
  • 31.15. Rallybio LLC

32. Global Rare Hematology Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rare Hematology Market

34. Recent Developments In The Rare Hematology Market

35. Rare Hematology Market High Potential Countries, Segments and Strategies

  • 35.1 Rare Hematology Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Rare Hematology Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Rare Hematology Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer